Order Article Reprints

Kauer V, Totschnig D, Waldenberger F, Augustin M, Karolyi M, Nägeli M, Wenisch C, Zoufaly A. Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19. Viruses. 2023; 15(5):1181. https://doi.org/10.3390/v15051181

Kauer, Victoria, David Totschnig, Ferdinand Waldenberger, Max Augustin, Mario Karolyi, Michelle Nägeli, Christoph Wenisch, and Alexander Zoufaly. 2023. "Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19" Viruses 15, no. 5: 1181. https://doi.org/10.3390/v15051181

Kauer, V., Totschnig, D., Waldenberger, F., Augustin, M., Karolyi, M., Nägeli, M., Wenisch, C., & Zoufaly, A. (2023). Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19. Viruses, 15(5), 1181. https://doi.org/10.3390/v15051181